Chemical Genomics

John S. Dunn Gulf Coast Consortium for Chemical Genomics

Putting Gulf Coast investigators ahead of the game in making groundbreaking drug advances and exciting new genome insights.

When the John S. Dunn Gulf Coast Consortium for Chemical Genomics (GCC CG) was organized in 2003, many Gulf Coast institution research laboratories were engaged in screening projects, but they were generally too small to be effective. To reduce the duplication of effort and to expand the screening capabilities, the GCC CG was organized as a research consortium to bring together scientists interested in this area of research with the aim of developing an inter-institutional academic drug discovery program.

The GCC CG’s Screening Lab and Satellite Facilities include the latest automation equipment for assay development and advanced central screening laboratories.

Texas Screening Alliance for Cancer Theraputics

About GCC CG

Small Molecules for Research and Medicine

The overall goal of the GCC CG has been to embed within each of the GCC institutions the capability of supporting high throughput and high content screening research projects through an integrated program of specialized equipment and expertise that would be available to individual researchers and research groups. Our strategy has always been to tailor our organization and its operations to match the priorities and the unique capabilities of an academic research center and to build upon the framework of inter-institutional collaboration embodied in the GCC.

In addition, the Chemical Genomics Consortium has established a Central High-throughput Screening Laboratory capable of serving as a Core Lab to support large screens for researchers from all the GCC institutions. A special emphasis of the Chemical Genomics Consortium has been on the development of a specialized capability in the application of cell-based imaging technologies to chemical genomics research.

As an academic research program, we are interested in exploring how these new technologies can be applied to “non-traditional” targets and to complex biological processes to develop new tools to probe the function of the genome.

John S. Dunn, GCC for Chemical Genomics Member Institutions

Baylor College of Medicine
Rice University
Texas Southern University
Houston Methodist Research Institute
University of Houston
The University of Texas Health Science Center at Houston
The University of Texas Medical Branch at Galveston
The University of Texas M. D. Anderson Cancer Center
The Institute of Biosciences and Technology of Texas A&M Health Science Center

Show less
GCC CG Leadership

John S. Dunn GCC Chemical Genomics Co-Directors

Peter Davies, M.D., Ph.D.
Director, Center for Translational Cancer Research
Institute of Biosciences & Technology
Texas A&M Health Science Center

Michael A. Mancini, Ph.D.
Associate Professor
Department of Molecular & Cellular Biology
Baylor College of Medicine

John S. Dunn GCC Chemical Genomics Executive Committee

Martin M. Matzuk, M.D., Ph.D.
Professor, Department of Molecular and Human Genetics
Stuart A. Wallace Chair and Professor, Department of Pathology & Immunology
Baylor College of Medicine

Orla Conneely, Ph.D.
Professor, Department of Molecular and Cellular Biology
Baylor College of Medicine

Scott R. Gilbertson, Ph.D.
M. D. Anderson Professor, Department of Chemistry
University of Houston

Philip Jones, Ph.D.
Head of Drug Discovery, Institute for Applied Cancer Science
The University of Texas M.D. Anderson Cancer Center

Stanley Watowich, Ph.D.
Associate Professor, Department of Biochemistry & Molecular Biology
Scientist, Sealy Center for Structural Biology & Molecular Biophysics
University of Texas Medical Branch-Galveston

Kathleen S. Matthews, Ph.D.
Stewart Memorial Professor, Biochemistry & Cell Biology
Rice University

Stephen T.C. Wong, Ph.D.
John S Dunn Distinguished Chair Professor of Radiology, Neurology, & Neurosciences
Director, Bioinformatics & Biomedical Engineering Program
The Methodist Hospital Research Institute

Show less
Texas Screening Alliance for Cancer Therapeutics

The Texas Screening Alliance for Cancer Therapeutics organizes and operates a multi-institutional research consortium that provides Texas’ cancer researchers with access to expertise and high-throughput technologies critical for drug discovery research. To achieve these aims the TxSACT Program has assembled a team of outstanding scientists in a multi-institutional consortium, organized under the auspices of the Gulf Coast Consortia.

By increasing the capacity and the accessibility of academic drug discovery research, the new TxSCAT Program is aligned with CPRIT’s mission to “create and expedite innovation in the area of cancer research, thereby enhancing the potential for a medical or scientific breakthrough in the prevention of cancer and cures for cancer.” TxSACT is funded by a Multi-Investigator Research Award from the Cancer Prevention and Research Institute of Texas.


Gulf Coast Consortia awarded $12.6 million for cancer research

HOUSTON-(March 31, 2011)- The Gulf Coast Consortia has been awarded a grant of more than $12.6 million from the Cancer Prevention Research Institute of Texas (CPRIT) to launch a collaborative program that brings together researchers with the common purpose of developing new cancer treatments.

The Gulf Coast Consortia CPRIT Throughput Screening Program, a component of the John S. Dunn Gulf Coast Consortium for Chemical Genomics, is designed to provide Texas’ researchers with access to resources normally only available to scientists working in large pharmaceutical companies. Robotic machines and chemicals will be among the available resources.

“We are thrilled that the work of the Gulf Coast Consortia is being recognized in this way, and we look forward to seeing the results of this collaboration,” said Kathleen Matthews, Ph.D., chair of the Gulf Coast Consortia Oversight Committee and the Stewart Memorial Professor of Biochemistry and Cell Biology at Rice University. “By providing access to these resources, the program will help researchers translate the important discoveries that are being made in the research laboratory into new treatments for this important disease category.”

Peter Davies, M.D., Ph.D., provost and executive vice president for research at The University of Texas Health Science Center at Houston (UTHealth), is the principal investigator and will also serve as the program’s co-director with Michael Mancini, Ph.D., associate professor and director of the Integrated Microscopy Core at Baylor College of Medicine.

“The primary goal of the program will be to accelerate the movement of basic discoveries in cancer research into clinical application through provision of critical resources to support drug discovery research and therapeutics development in Texas,” Davies said. “By combining state-of-the-art laboratory technologies with a sophisticated program of informatics for data mining and data sharing, the program will allow cancer researchers to pick the most promising leads, new molecules or drugs that have the highest probability of success in their path to development of new cancer therapies.”

The Gulf Coast Consortia brings together the strengths of its six member institutions to build interdisciplinary collaborative research teams and training programs in the biological sciences at their intersection with the computational, chemical, mathematical and physical sciences. It is composed of UTHealth, Baylor College of Medicine, Rice University, University of Houston, The University of Texas Medical Branch at Galveston and The University of Texas MD Anderson Cancer Center.

“This new award from CPRIT will greatly expand drug discovery capabilities for cancer therapeutics. Baylor College of Medicine is proud to be a part of the Gulf Coast Consortia’s programs to foster collaboration among scientists in the Gulf Coast region,” said Timothy Palzkill, Ph.D., professor and chair of the Department of Pharmacology at Baylor College of Medicine.

Working on various elements of the CPRIT Throughput Screening Program funded by the grant are UTHealth, The University of Texas MD Anderson Cancer Center, The University of Texas at Austin, Rice University, Baylor College of Medicine and The Methodist Hospital Research Institute.

“This is an exciting opportunity for the drug development efforts at UT Austin’s Texas Institute for Drug and Diagnostics Development. By partnering with the Gulf Coast Consortia, we are able to leverage efforts and capabilities in Austin with those of the Houston area institutions. Such an unprecedented level of research coordination across the state of Texas is an innovation in itself, one that will lead to a very fertile foundation for many breakthroughs in our fight against cancer,” said Brent Iverson, Ph.D., the Warren J. and Viola Mae Raymer Professor and chairman of the Department of Chemistry and Biochemistry at UT Austin.

Stephen Wong, Ph.D., the John S Dunn Distinguished Endowed Chair in Biomedical Engineering and professor of radiology, neurosciences, pathology and laboratory medicine at The Methodist Hospital Research Institute , added, “This allows us to be a hub and put Texas on the map in high throughput drug discovery nationally. We at Methodist are proud to be part of the team that will process, analyze, manage and turn mountains of drug screening information into credible hits for cancer drugs. We’ll also be able to combine these high throughput data with genomic and drug databases to identify underlying molecular pathway mechanism of various type of cancer.”

Building upon support from the John S. Dunn Foundation and UTHealth’s Clinical and Translational Sciences Award from the National Institutes of Health, the program will include technology and administrative cores, plus an information exchange network to promote collaboration and data sharing among Texas cancer researchers.

“This is very exciting news for the institutions involved and for the development of state-of-the-art high throughput technologies that can be applied to cancer research in Texas. It will help investigators identify new targets, new agents and approaches to the treatment of cancer, ultimately benefiting patients in Texas and nationwide,” said Garth Powis, D. Phil, chair of the Department of Experimental Therapeutics and director of the Center for Targeted Therapy at MD Anderson Cancer said.

Members of Gulf Coast Consortia and its oversight committees said the CPRIT award represents the consortia’s collaborative spirit.

“Rice is eager to play its role as a partner in the education and information exchange aspect of this vitally important program that will accelerate the development of cancer therapeutics,” said Daniel Carson, Ph.D., dean and Schlumberger Chair of Advanced Studies and Research at the Wiess School of Natural Sciences at Rice University.

Texas leads the nation in its commitment to curing cancer. In 2007, Texas voters overwhelmingly approved a constitutional amendment establishing the Cancer Prevention and Research Institute of Texas (CPRIT) and dedicating up to $3 billion to invest in groundbreaking cancer research and prevention programs and services in Texas. CPRIT focuses on expediting the innovation and commercialization of cancer research – in turn increasing the potential for a medical or scientific breakthrough – and enhancing access to evidence-based prevention programs and services.

“We are very excited that the high throughput screening program will provide tools that will accelerate identification and development of new cancer therapeutics,” said William New, associate dean for research administration at The University of Texas Medical Branch at Galveston.

For more information, visit

Meredith Raine
Media Hotline: 713-500-3030

Show less